Lv11
60 积分 2022-06-21 加入
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
4小时前
已完结
Microsatellite Instability Testing Using Next-Generation Sequencing Data and Therapy Implications
18天前
已完结
Classification and characterization of microsatellite instability across 18 cancer types
3个月前
已完结
WRN Helicase: Is There More to MSI-H than Immunotherapy?
3个月前
已完结
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
7个月前
已完结
Clinical Benefit and Regulatory Outcomes of Cancer Drugs Receiving Accelerated Approval
7个月前
已完结
How a controversial US drug policy could be harming cancer patients worldwide
8个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
1年前
已完结
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
2年前
已完结
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
2年前
已完结
皖公网安备34019202002308
